Iroko Pharmaceuticals Appoints New Member To Company's Board Of Directors

PHILADELPHIA, April 1, 2015 — Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced the appointment of Pierre Legault to its board of directors. Mr. Legault, who is currently Chief Executive Officer of NephroGenex, Inc., brings extensive commercialization experience to the Company. He formerly served as Chief Executive Officer at Prosidion, Ltd. and has held senior management positions at OSI Pharmaceuticals, Eckerd, Rite Aid Corporation, and Sanofi-Aventis.

"I am proud to welcome Mr. Legault to the Iroko team," said Osagie Imasogie, Executive Chairman of the Board and Chief Executive Officer of Iroko Pharmaceuticals. "We are confident that his broad understanding of this industry and significant pharmaceutical operations experience will be a valuable asset for Iroko as we continue to expand and commercialize our portfolio of low dose SoluMatrix® NSAIDs."

Mr. Legault joined Pennsylvania-based pharmaceutical company NephroGenex in 2013, having previously served as a member and Executive Chairman of its board of directors. He has previously held management positions at other pharmaceutical and biotechnology companies, including the roles of CEO of Prosidion, Ltd., and Executive Vice President, Chief Financial Officer and Treasurer of OSI Pharmaceuticals. Mr. Legault also brings pharmacy operations experience to Iroko, having served as Executive Vice President and Chief Administrative Officer of Rite Aid Corporation, and President of Eckerd Group. Mr. Legault has also held several senior positions with Sanofi-Aventis. Previous corporate boards on which he served include Forest Laboratories, Inc., NPS Pharmaceuticals, Regado Biosciences, Cyclacel Pharmaceuticals, Inc., The Jean Coutu Group (PJC) Inc. and several others.

"In a short time since the company's inception, Iroko has already established itself as a strong force in the pain management space with products approved for patients suffering from acute and chronic pain conditions and a rich pipeline of low dose SoluMatrix® NSAIDs in development," said Mr. Legault. "I'm honored to join a company with such a focused mission that has already achieved impressive success, and am looking forward to bringing my extensive industry experience to Iroko as the company continues toward an exciting future."

About Iroko Pharmaceuticals, LLC

Iroko is a global specialty pharmaceutical company, based in Philadelphia, dedicated to advancing the science of analgesia. The company develops and globally commercializes pharmaceutical products. Iroko is at the forefront of the development of SoluMatrix® NSAIDs – new low dose drug products based on existing NSAIDs – using iCeutica Inc.'s proprietary SoluMatrix Fine Particle Technology™ exclusively licensed to Iroko for NSAIDs. The first SoluMatrix® NSAID is available in pharmacies and a second was approved by FDA. For more information, visit


Jessica Donnelly for Iroko Pharmaceuticals, LLC, 212-798-9819

Kate de Santis, Iroko Pharmaceuticals, LLC, 267-546-1682

SoluMatrix Fine Particle Technology™ is a trademark of iCeutica Inc., and the technology is licensed to Iroko for exclusive use in NSAIDs.

SoluMatrix® is a trademark of iCeutica Pty Ltd and is licensed to Iroko.

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.